Patents Issued in October 12, 2017
-
Publication number: 20170291858Abstract: An assemblable appliance and method of recycling organic waste into biogas and liquid fertilizer, implementing essentially anaerobic digestion processes, is described. The assemblable appliance includes: a pliant structured exoskeletal envelope, pliable collapsible anaerobic digester and gas tank. A compact kit-of-parts for assembling the aforementioned appliance and respective method using the aforementioned appliance for recycling organic waste into biogas and liquid fertilizer are described.Type: ApplicationFiled: June 25, 2017Publication date: October 12, 2017Applicant: HOME BIOGAS LTDInventors: Oshik Moshe EFRATI, Yair TELLER, Erez LANZER, Shoham ZAK
-
Publication number: 20170291859Abstract: The invention concerns a process for the production of butadiene from an ethanol feed comprising at least 80% by weight of ethanol, comprising at least one step A) for the conversion of ethanol into acetaldehyde A), a step B) for converting an ethanol/acetaldehyde mixture into butadiene, a step C1) for hydrogen treatment, a step D1) for butadiene extraction, a first butadiene purification step D2), a subsequent butadiene purification step D3), an effluent treatment step E1), a step E2) for eliminating impurities and brown oils and a step F) for scrubbing with water.Type: ApplicationFiled: September 17, 2015Publication date: October 12, 2017Applicants: IFP Energies nouvelles, Compagnie Generale des Etablissements Michelin, MICHELIN RECHERCHE ET TECHNIQUE S.A.Inventors: Rejane DASTILLUNG, Beatrice FISCHER, Marc JACQUIN, Raphael HUYGHE
-
Publication number: 20170291860Abstract: Apparatus and methods are provided for converting methane in a feed stream to acetylene. A hydrocarbon stream is introduced into a supersonic reactor and pyrolyzed to convert at least a portion of the methane to acetylene. The reactor effluent stream may be treated to convert acetylene to another hydrocarbon process.Type: ApplicationFiled: June 21, 2017Publication date: October 12, 2017Inventors: Robert L. Bedard, Christopher Naunheimer, Gavin P. Towler, Laura E. Leonard, Rodolphe Dudebout, Gregory O. Woodcock, Donald L. Mittendorf, Aziz Sattar, Christopher D. Gatto, Robert S. Murray
-
Publication number: 20170291861Abstract: Apparatus and methods are provided for converting methane in a feed stream to acetylene. A hydrocarbon stream is introduced into a supersonic reactor and pyrolyzed to convert at least a portion of the methane to acetylene. The reactor effluent stream may be treated to convert acetylene to another hydrocarbon process.Type: ApplicationFiled: June 22, 2017Publication date: October 12, 2017Inventors: Robert L. Bedard, Christopher Naunheimer, Gavin P. Towler, Laura E. Leonard, Gregory O. Woodcock, Donald L. Mittendorf, Aziz Sattar, Christopher D. Gatto, Robert S. Murray
-
Publication number: 20170291862Abstract: A method for producing at least one olefin compound selected from the group consisting of a compound of formula (51), a compound of formula (52), a compound of formula (53), and a compound of formula (54), the method including reacting an olefin compound of formula (21) with a olefin compound of formula (31) in the presence of at least one metal catalyst selected from the group consisting of a compound of formula (11), a compound of formula (12), a compound of formula (13), a compound of formula (14), and a compound of formula (15).Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Applicant: ASAHI GLASS COMPANY, LIMITEDInventor: Yusuke TAKAHIRA
-
Publication number: 20170291863Abstract: A method for producing at least one olefin compound selected from the group consisting of a compound of formula (51) and a compound of formula (52), the method including reacting an olefin compound of formula (21) with a olefin compound of formula (31) in the presence of at least one metal catalyst selected from the group consisting of a compound of formula (11), a compound of formula (12), a compound of formula (13), a compound of formula (14), and a compound of formula (15).Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Applicant: ASAHI GLASS COMPANY, LIMITEDInventors: Yusuke TAKAHIRA, Daisuke JOMUTA
-
Publication number: 20170291864Abstract: A method includes brominating a butanes feed stream including i-butane in a bromination reactor to form a bromination effluent stream including t-butyl bromide. The method includes dehydrobrominating the t-butyl bromide to form isobutylene. Another method includes brominating a mixed pentanes feed stream including i-pentane and n-pentane in a bromination reactor to form a bromination effluent stream including t-pentyl bromide. The method includes dehydrobrominating the t-pentyl bromide to form isoamylene and HBr.Type: ApplicationFiled: September 15, 2015Publication date: October 12, 2017Inventors: Jeffrey H. Sherman, Peter K. Stoimenov
-
Publication number: 20170291865Abstract: A polyfluoroalkyl allyl compound represented by the general formula: CF3(CF2)n(CH2CF2)a(CF2CF2)bCH2CH?CH2??[I] (n: 0 to 5, a: 1 or 2, b: 0 to 3). The polyfluoroalkyl allyl compound is produced by reacting a carboxylic acid allyl adduct represented by the general formula: CF3(CF2)n(CH2CF2)a(CF2CF2)bCH2CHICH2OCOR???[II] (n, a, and b are as defined above, and R?: a C1-C3 alkyl group) with a transition metal. This method for producing provides a polyfluoroalkyl allyl compound used as a synthetic intermediate for a fluorine-containing alkylsilane compound that can remove free iodine derived from the raw material compound, before a hydrosilylation reaction is performed, without using a metal reagent having a high environmental impact, and that has excellent handling properties.Type: ApplicationFiled: September 18, 2015Publication date: October 12, 2017Applicant: UNIMATEC CO., LTD.Inventor: Takeshi FUKUSHIMA
-
Publication number: 20170291866Abstract: A method for producing mixed aldol products from the products of hydroformylation reactions. In one embodiment, the method comprises mixing hydroformylation reaction products comprising aldehydes with a catalyst inside a reactor to create a mixture. The method also includes agitating the mixture at a temperature in a range of between about 200° F. to about 275 ° F. to create a reacted mixture. The reacted mixture is then cooled in the reactor to create an organic phase and an aqueous phase. The organic phase is pumped out of the reactor and may then be transferred to a distillation tower. The organic phase may be distilled until any mixed aldol products are isolated, wherein the mixed aldol products may be subsequently removed.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Applicant: Texmark Chemicals, Inc.Inventors: Rajeshwari Kannan, Rebecca L. Rosas
-
Publication number: 20170291867Abstract: A process for ring hydrogenation of a benzenepolycarboxylic acid or derivative thereof, includes contacting a feed stream comprising the acid or derivative thereof with a hydrogen containing gas in the presence of a catalyst under hydrogenation conditions to produce a hydrogenated product, wherein the catalyst contains rhodium and ruthenium.Type: ApplicationFiled: October 9, 2015Publication date: October 12, 2017Inventors: Stuart L. Soled, Sabato Miseo, Joseph E. Baumgartner, Christine E. Kliewer, Hans K. T. Goris
-
Publication number: 20170291868Abstract: The invention includes a diester exhibiting improved hydrolytic stability that is an esterification product of a 1-methylheptyl alcohol and a dicarboxylic acid. In some embodiments, the diester is bis(1-methyl heptyl) butanedioate, bis(1-methyl heptyl) nonanedioate and/or bis(1-methyl heptyl) decanedioate. The diester may be natural and/or not sourced from palm. Also contemplated within the scope of the invention are diesters exhibiting improved hydrolytic stability represented by Formula (I): wherein R1 is chosen from a linear alkyl group containing four to ten carbon atoms.Type: ApplicationFiled: April 7, 2017Publication date: October 12, 2017Inventors: Rocco Burgo, Daniel Winn
-
Publication number: 20170291869Abstract: The invention relates to a method for producing dinitrotoluene, comprising the following steps: a) nitrating toluene with a mixture of nitric acid and sulfuric acid and subsequently separating a sulfuric-acid-containing aqueous phase that arises in the nitration, wherein a raw dinitrotoluene is obtained, b) washing the raw dinitrotoluene in a water wash with neutral and/or alkaline washing water, wherein a pre-cleaned dinitrotoluene, which contains at least water in addition to dinitrotoluene, is obtained after the washing water used in the last wash has been separated, and c) separating the water from the pre-cleaned dinitrotoluene, d) collecting the waste water from steps a), b), and/or c), e) optionally extracting the collected waste water from step d) with toluene and returning the thus obtained organic phase to step a), f) freeing the collected waste water from step d), or, if the optional step e) is performed, the extracted waste water from step e), of toluene in a toluene stripper, wherein a toluene-coType: ApplicationFiled: September 29, 2015Publication date: October 12, 2017Inventors: Thomas KNAUF, Jürgen MÜNNIG, Wolfgang LORENZ, Bernd PENNEMANN
-
Publication number: 20170291870Abstract: The present invention relates to an amide compound solution comprising an amide compound and a surfactant. More specifically, the invention relates to an amide compound solution comprising amide compound, and 2.7˜20 mg of a cationic surfactant per 1 kg of the amide compound or 0.01˜10 mg of a C15˜C20 carboxylic acid or its salt as an anionic surfactant per 1 kg of the amide compound. The present invention provides an amide compound solution which is manufactured using a biocatalyst and which has a low level of foaming, and thereby improving the operability and yield when manufacturing an amide compound-based polymer.Type: ApplicationFiled: February 15, 2016Publication date: October 12, 2017Applicant: Mitsubishi Rayon Co., Ltd.Inventors: Makoto KANO, Norifumi HAGIYA
-
Publication number: 20170291871Abstract: Novel 2,2?-diaminobiaryls having one primary and one secondary amine and an electrochemical process for preparation thereof.Type: ApplicationFiled: July 23, 2015Publication date: October 12, 2017Applicant: EVONIK DEGUSSA GMBHInventors: Katrin Marie DYBALLA, Robert FRANKE, Dirk FRIDAG, Siegfried R. WALDVOGEL, Bernd ELSLER, Mathias ENDERS
-
Publication number: 20170291872Abstract: Compositions comprising branched C10 mercaptans selected from the group consisting of 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, and combinations thereof.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Inventors: Michael S. Matson, Jim D. BYERS, Jason L. KREIDER
-
Publication number: 20170291873Abstract: A process includes reacting, in a reactor having a fixed bed containing a solid catalyst which contains a heterogeneous ion exchange resin, hydrogen sulfide and ethylene oxide in the presence of the solid catalyst to yield a reaction product which contains beta-mercaptoethanol. A reactor system includes the reactor, an ethylene oxide stream, a hydrogen sulfide stream, a fixed bed containing the solid catalyst placed in the reactor, and an effluent stream containing the reaction product. During steady state operation of the reactor in the process and the reactor system, the hydrogen sulfide and the ethylene oxide are present in a mole ratio in a range of about 9:1 to about 20:1.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Inventors: Daniel M. HASENBERG, Alex PAUWELS
-
Publication number: 20170291874Abstract: The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Applicant: H. Lundbeck A/SInventors: Mikkel Fog Jacobsen, Florian Anton Martin Huber
-
Publication number: 20170291875Abstract: The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:Type: ApplicationFiled: August 28, 2015Publication date: October 12, 2017Inventors: Paul Vincent Fish, Niall Igoe, Elliott David Bayle
-
Publication number: 20170291876Abstract: A synthesis method of ?-nitropyrazole amide compound through asymmetrical catalyzing technique is provided, a nitroalkane and an ?,?-unsaturated pyrazole amide are applied as the raw material, a complex formed by a chiral amine oxide with a rare earth metal compound is served as the catalyst, a 4 ? molecular sieve is served as an additive, the ?-nitropyrazole amide compound can be obtained with a yield more than 99% and enantiomeric excess more than 99% ee. The catalytic system not only has the advantages of simple operation, mild reaction conditions, requiring no acid/base additives, convenient product purification, high yield and enatioselectivity, compliance with green atomic economy, and promising prospects for industrial application, but also allows the obtained ?-nitropyrazole amide compound to undergo some simple chemical conversions to produce some molecules having physiological activities.Type: ApplicationFiled: June 12, 2015Publication date: October 12, 2017Inventors: Xiaoming FENG, Qian YAO, Xiaohua LIU, Lili LIN, Yuheng ZHANG
-
Publication number: 20170291877Abstract: The present invention relates to antimicrobial imidazolium compounds having the structure of Formula (I) wherein R is an optionally substituted aliphatic group that is linear, cyclic, saturated, unsaturated or any combination thereof; n is an integer of at least 1; and X is an anionic counterion. The present invention also relates to pharmaceutical composition comprising the compound, a gel comprising the compound, uses of the compound as an antibiotic and methods for the preparation of the gels.Type: ApplicationFiled: September 15, 2015Publication date: October 12, 2017Inventors: Yugen ZHANG, Siti Nurhanna Binti RIDUAN, Yuan YUAN
-
Publication number: 20170291878Abstract: A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.Type: ApplicationFiled: September 17, 2015Publication date: October 12, 2017Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi UEDA, Kazutoshi UKAI
-
Publication number: 20170291879Abstract: A cancer cell proliferation inhibitor including at least one selected from compounds represented by Structural Formulae (1) to (8), wherein the cancer cell is at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant vIII.Type: ApplicationFiled: September 7, 2015Publication date: October 12, 2017Inventors: Sonoko Atsumi, Masabumi Shibuya, Shun-ichi Ohba, Tomoyuki Kimura, Yoshihiko Kobayashi, Hayamitsu Adachi, Chisato Nosaka, Akio Nomoto
-
Publication number: 20170291880Abstract: Disclosed is a process for the preparation of toltrazuril of formula (I) via the intermediate N-methyl-N?-[3-methyl-4-[4-[(trifluoromethyl)thio]phenoxy]phenyl] imidodicarbonic diamide of formula (III) wherein intermediate (III) is obtained via a novel intermediate without the use of potentially hazardous reagents or potentially unstable intermediates.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Inventors: Massimo Ferrari, Daniele De Zani, Matteo Bonaldi
-
Publication number: 20170291881Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.Type: ApplicationFiled: September 10, 2015Publication date: October 12, 2017Applicant: AhR Pharmaceuticals, Inc.Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
-
Publication number: 20170291882Abstract: Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.Type: ApplicationFiled: October 1, 2015Publication date: October 12, 2017Inventors: Allan W. Rey, Annyt Bhattacharyya, Jenny L. Gerster, Sammy Chris Duncan, Mohammed Abdul Raheem, Fan Wang, Stuart P. Green
-
Publication number: 20170291883Abstract: It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. The solution is crystals, or hydrate thereof, of a salt of a compound represented by formula (I).Type: ApplicationFiled: September 18, 2015Publication date: October 12, 2017Applicant: Daiichi Sankyo Company, LimitedInventors: Mizuka YOKOYAMA, Yasusi UEDA, Daisuke FUKATSU, Yuichi AKI
-
Publication number: 20170291884Abstract: The present invention relates to novel compounds and their use as malodor counteractant materials.Type: ApplicationFiled: September 25, 2015Publication date: October 12, 2017Applicant: International Flavors & Fragrances Inc.Inventors: Sean M. Wetterer, Drew T. Parkhurst, Richard Anthony Weiss, Anthony T. Levorse, Jr., Michael G. Monteleone, Richard M. Boden
-
Publication number: 20170291885Abstract: Provided is a method for preparing an enamide compound, which includes reacting an organic azide compound having ?-hydrogen and an anhydride by addition of a ruthenium complex catalyst in the presence of an ionic liquid, and a ruthenium complex catalyst used herein.Type: ApplicationFiled: March 30, 2017Publication date: October 12, 2017Inventors: Jai Wook PARK, Jin Yong PARK, Yong Jin KIM, Yea Rang KWON, Han Kyu PAK, Young Ho RHEE
-
Publication number: 20170291886Abstract: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.Type: ApplicationFiled: August 28, 2015Publication date: October 12, 2017Inventors: Stephen Page, Andrew Stevens, Adam McCluskey, Martine Keenan, Rebecca Abraham
-
Publication number: 20170291887Abstract: Filamenting temperature-sensitive mutant Z (FtsZ) protein plays a crucial role in the bacterial cell division machinery and is a validated drug target for antibacterial agents. The present invention relates to FtsZ-interacting compounds that possess a 2,4,6-trisubstituted pyrimidine scaffold. Some of these compounds possess potent anti-staphylococcal properties and potent antibacterial activities against clinically isolated MRSA strains. Compounds have been identified to exhibit low spontaneous frequency of resistance, low toxicity as well as the ability to rescue G. mellonella larvae infected with lethal dose of the MRSA ATCC 43300 strain. Characterization by saturation transfer difference NMR, light scattering assay and GTPase hydrolysis assay with purified S. aureus FtsZ protein verified the interaction of 2,4,6-trisubstituted pyrimidine with the FtsZ protein, further confirmed by observations of iconic filamentous cell phenotype and mislocalization of the Z-ring formation.Type: ApplicationFiled: September 29, 2016Publication date: October 12, 2017Inventors: Kwok-yin WONG, Tak-Hang CHAN, Kin-Fai CHAN
-
Publication number: 20170291888Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A21, or, particularly, the A2, receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whicType: ApplicationFiled: November 4, 2016Publication date: October 12, 2017Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
-
Publication number: 20170291889Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: September 16, 2015Publication date: October 12, 2017Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Timothy Claude BARDEN, James Edward SHEPPECK, Glen Robert RENNIE, Paul Allan RENHOWE, Nicholas PERL, Takashi NAKAI, Ara MERMERIAN, Thomas Wai-Ho LEE, Joon JUNG, James JIA, Karthik IYER, Rajesh R. IYENGAR, G-Yoon Jamie IM
-
Publication number: 20170291890Abstract: The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: September 17, 2015Publication date: October 12, 2017Inventor: John Emmerson Campbell
-
Publication number: 20170291891Abstract: The invention concerns novel substituted pyridine-piperazinyl analogues of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: June 23, 2017Publication date: October 12, 2017Inventors: Jerôme Emile Georges GUILLEMONT, David Francis Alain LANÇOIS, Magali Madeleine Simone MOTTE, Delphine Yvonne Raymonde LARDEAU, Xavier Marc BOURDREZ, Wendy Mia Albert BALEMANS, Dirk André Emmy ROYMANS
-
Publication number: 20170291892Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.Type: ApplicationFiled: September 22, 2015Publication date: October 12, 2017Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Susanne RÖHRIG, Eloisa JIMENEZ-NUNEZ, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Henrik TELLER, Alexander HILLISCH, Stefan HEITMEIER, Martina Victoria SCHMIDT, Jens ACKERSTAFF, Jan STAMPFUß
-
Publication number: 20170291893Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.Type: ApplicationFiled: June 27, 2017Publication date: October 12, 2017Inventors: Daniel A. Lawrence, Cory Emal, Ashley Reinke, Shih-Hon Li, Mark Warnock, Gregory Abernathy
-
Publication number: 20170291894Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.Type: ApplicationFiled: April 4, 2017Publication date: October 12, 2017Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
-
Publication number: 20170291895Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: ApplicationFiled: June 15, 2017Publication date: October 12, 2017Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
-
Publication number: 20170291896Abstract: Disclosed are a compound of formula (I), a tautomer, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the above-mentioned compounds. The above-mentioned compounds have the activity of inhibiting Xa factor positive effect, and can be used for the preparation of a medicament for preventing and/or treating diseases inhibiting Xa factor positive effect in case of low bleeding risk.Type: ApplicationFiled: September 2, 2015Publication date: October 12, 2017Inventors: Ying SHI, Qingzhi GAO, Yi MI, Xuliang WANG
-
Publication number: 20170291897Abstract: The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.Type: ApplicationFiled: September 3, 2015Publication date: October 12, 2017Inventors: Emma Louise Blaney, Barrie Phillip Martin, Thorsten Nowak, Martin John Watson
-
Publication number: 20170291898Abstract: The present invention provides a life-extending agent comprising pyrroloquinoline quinone and/or a derivative of the pyrroloquinoline quinone.Type: ApplicationFiled: September 18, 2015Publication date: October 12, 2017Applicants: National University Corporation Nagoya University, Mitsubishi Gas Chemical Company, Inc.Inventors: Ikue MORI, Hiroyuki SASAKURA, Kazuto IKEMOTO, Masahiko NAKANO
-
Publication number: 20170291899Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, Ri does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.Type: ApplicationFiled: September 22, 2015Publication date: October 12, 2017Inventors: Niall Andrew ANDERSON, Ian Baxter CAMPBELL, Matthew Howard James CAMPBELL-CRAWFORD, Ashley Paul HANCOCK, Seble LEMMA, Simon John Fawcett MACDONALD, John Martin PRITCHARD, Panayiotis Alexandrou PROCOPIOU
-
Publication number: 20170291900Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: June 27, 2017Publication date: October 12, 2017Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
-
Publication number: 20170291901Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Applicant: H. Lundbeck A/SInventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
-
Publication number: 20170291902Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, JB, n, JD, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.Type: ApplicationFiled: September 16, 2015Publication date: October 12, 2017Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Nicholas PERL, Takashi NAKAI, Thomas Wai-Ho LEE, Glen Robert RENNIE, Paul Allan RENHOWE, Rajesh R. IYENGAR
-
Publication number: 20170291903Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.Type: ApplicationFiled: June 6, 2017Publication date: October 12, 2017Applicant: H. Lundbeck A/SInventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
-
Publication number: 20170291904Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: ApplicationFiled: September 17, 2015Publication date: October 12, 2017Inventors: Peng LI, Hailin ZHENG, Jun ZHAO, Lawrence WENNOGLE
-
Publication number: 20170291905Abstract: Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.Type: ApplicationFiled: September 17, 2015Publication date: October 12, 2017Applicant: Epizyme, Inc.Inventors: Richard Chesworth, Lorna Helen Mitchell, John Emmerson Campbell, Lawrence Alan Reiter, Kerren Kalai Swinger
-
Publication number: 20170291906Abstract: Compounds of formula III: and salts thereof are disclosed. Also disclosed are methods for preparing compounds of formula III, intermediates useful for preparing compounds of formula III and methods for preparing compounds and materials from compounds of formula III.Type: ApplicationFiled: March 30, 2017Publication date: October 12, 2017Inventors: Thomas R. Hoye, Ashok Pehere, Shu Xu
-
Publication number: 20170291907Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rinType: ApplicationFiled: February 20, 2017Publication date: October 12, 2017Inventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec